$IRON
Disc Medicine, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004464 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.108M $4.995M $500.0K
YoY Change 1547.74% 899.0%
% of Gross Profit
Research & Development $12.63M $13.46M $6.727M
YoY Change 100.01%
% of Gross Profit
Depreciation & Amortization $46.00K $58.00K
YoY Change
% of Gross Profit
Operating Expenses $17.74M $18.45M $7.949M
YoY Change 5623.23% 132.1%
Operating Profit -$18.45M -$7.949M
YoY Change 132.1%
Interest Expense -$81.00K $104.0K $2.047M
YoY Change -94.92%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$17.82M -$18.55M -$500.0K
YoY Change 5649.35% 3610.2%
Income Tax
% Of Pretax Income
Net Earnings -$17.82M -$18.55M -$10.00M
YoY Change 5649.35% 85.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.43
Diluted Earnings Per Share -$412.9K -$430.5K -$39.94K
COMMON SHARES
Basic Shares Outstanding 43.11M 43.09M
Diluted Shares Outstanding 43.09M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $136.6M $150.1M $1.400M
YoY Change 11285.58% 10619.21%
Cash & Equivalents $136.6M $150.1M $13.54M
Short-Term Investments
Other Short-Term Assets $3.473M $4.731M $200.0K
YoY Change 3373.0% 2265.5%
Inventory
Prepaid Expenses $3.250M $4.731M
Receivables
Other Receivables
Total Short-Term Assets $140.1M $154.8M $1.600M
YoY Change 2666.04% 9575.0%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $180.0K
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $237.0K $232.0K $120.8M
YoY Change -99.8% -99.81%
Total Long-Term Assets $337.0K $735.0K $120.8M
YoY Change -89.64% -99.39%
TOTAL ASSETS
Total Short-Term Assets $140.1M $154.8M $1.600M
Total Long-Term Assets $337.0K $735.0K $120.8M
Total Assets $140.4M $155.5M $122.4M
YoY Change 1588.15% 27.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.950M $939.0K $0.00
YoY Change 24.11%
Accrued Expenses $6.884M $6.722M $500.0K
YoY Change 1276.8% 1244.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $5.000M
YoY Change -57.22%
Total Short-Term Liabilities $14.83M $12.66M $600.0K
YoY Change -40.37% 2010.17%
LONG-TERM LIABILITIES
Long-Term Debt $404.0K $1.647M $0.00
YoY Change
Other Long-Term Liabilities $358.0K $366.0K $4.200M
YoY Change -91.48% -91.29%
Total Long-Term Liabilities $762.0K $2.013M $4.200M
YoY Change -81.86% -52.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.83M $12.66M $600.0K
Total Long-Term Liabilities $762.0K $2.013M $4.200M
Total Liabilities $15.60M $14.67M $4.800M
YoY Change -48.32% 205.71%
SHAREHOLDERS EQUITY
Retained Earnings -$184.7M -$166.9M
YoY Change 63.7%
Common Stock $4.000K $4.000K
YoY Change 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.8M $140.9M -$8.278M
YoY Change
Total Liabilities & Shareholders Equity $140.4M $155.5M $122.4M
YoY Change 1588.15% 27.07%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$17.82M -$18.55M -$10.00M
YoY Change 5649.35% 85.45%
Depreciation, Depletion And Amortization $46.00K $58.00K
YoY Change
Cash From Operating Activities -$12.67M -$16.10M -$190.0K
YoY Change 5407.83% 8372.11%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$61.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $415.0K -$120.8M
YoY Change
Cash From Investing Activities $405.0K -$61.00K -$120.8M
YoY Change -99.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.179M -1.250M 122.4M
YoY Change -101.02%
NET CHANGE
Cash From Operating Activities -12.67M -16.10M -190.0K
Cash From Investing Activities 405.0K -61.00K -120.8M
Cash From Financing Activities -1.179M -1.250M 122.4M
Net Change In Cash -13.44M -17.41M 1.410M
YoY Change 5744.35% -1334.61%
FREE CASH FLOW
Cash From Operating Activities -$12.67M -$16.10M -$190.0K
Capital Expenditures -$10.00K -$61.00K
Free Cash Flow -$12.66M -$16.04M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
562000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
154800000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
5065000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
180000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
294000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
323000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001816736
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Gemini Therapeutics, Inc. /DE
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39438
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1612845
dei Entity Address Address Line1
EntityAddressAddressLine1
300 One Kendall Square, 3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
401-4400
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
GMTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43112742
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150069000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4503000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4731000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
323000
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
2637000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
232000
CY2021Q3 us-gaap Assets
Assets
155535000
CY2020Q4 us-gaap Assets
Assets
8319000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
939000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2377000
CY2021Q3 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6722000
CY2020Q4 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5810000
CY2021Q3 us-gaap Loans Payable Current
LoansPayableCurrent
5000000
CY2020Q4 us-gaap Loans Payable Current
LoansPayableCurrent
5000000
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
11689000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12661000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24876000
CY2020Q4 gmtx Warrant Liability
WarrantLiability
76000
CY2021Q3 us-gaap Other Liabilities
OtherLiabilities
366000
CY2020Q4 us-gaap Other Liabilities
OtherLiabilities
277000
CY2021Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
1647000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
4951000
CY2021Q3 us-gaap Liabilities
Liabilities
14674000
CY2020Q4 us-gaap Liabilities
Liabilities
30180000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43112742
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43112742
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15565380
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15565380
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
307724000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
90958000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166867000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112821000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
140861000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-21861000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155535000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8319000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13455000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6727000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7949000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36083000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20472000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4995000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1222000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15177000
us-gaap Operating Expenses
OperatingExpenses
51260000
us-gaap Operating Expenses
OperatingExpenses
24246000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18450000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3774000
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
94000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9746000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
18450000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
7949000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51260000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24246000
CY2021Q3 us-gaap Interest Expense
InterestExpense
104000
CY2020Q3 us-gaap Interest Expense
InterestExpense
2047000
us-gaap Interest Expense
InterestExpense
2073000
us-gaap Interest Expense
InterestExpense
2307000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
711000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18551000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10003000
us-gaap Net Income Loss
NetIncomeLoss
-54046000
us-gaap Net Income Loss
NetIncomeLoss
-26522000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.77
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43091822
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15282987
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39427476
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15016038
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-10432000
CY2020Q1 gmtx Issuance Of Convertible Preferred Stock Net Of Issuance Costs
IssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
148000
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
20084000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
10000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2020Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
138000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6773000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-6616000
CY2020Q3 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
8177000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
161000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10003000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-8278000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-21861000
CY2021Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
195882000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
14515000
CY2021Q1 gmtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
76000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1593000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-19048000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
171161000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
106000
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
2862000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16447000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
157682000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
71000
CY2021Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1659000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18551000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
140861000
us-gaap Profit Loss
ProfitLoss
-54046000
us-gaap Profit Loss
ProfitLoss
-26522000
us-gaap Depreciation
Depreciation
185000
us-gaap Depreciation
Depreciation
235000
us-gaap Share Based Compensation
ShareBasedCompensation
6114000
us-gaap Share Based Compensation
ShareBasedCompensation
393000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
257000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
279000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
711000
gmtx Accretion Of Discount On Convertible Notes
AccretionOfDiscountOnConvertibleNotes
1600000
gmtx Accretion Of Discount On Convertible Notes
AccretionOfDiscountOnConvertibleNotes
1778000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4098000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1249000
gmtx Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
-1341000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
232000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-459000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1478000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1595000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
205000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47032000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23855000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
61000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-61000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22000
gmtx Proceeds From Business Combination Net
ProceedsFromBusinessCombinationNet
195882000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20084000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
14000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
110000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22000
gmtx Principal Payments On Term Loan
PrincipalPaymentsOnTermLoan
3333000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
192659000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34106000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
145566000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10229000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4826000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3309000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150392000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13538000
us-gaap Interest Paid Net
InterestPaidNet
248000
us-gaap Interest Paid Net
InterestPaidNet
250000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
14515000
gmtx Exercise Of Warrants
ExerciseOfWarrants
76000
gmtx Proceeds From Exercise Of Stock Options Included In Other Current Assets
ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets
71000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
us-gaap Notes Reduction
NotesReduction
8177000
gmtx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
1341000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of the business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gemini Therapeutics, Inc. (the “Company” or “Gemini”) is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The Company was founded on March 3, 2015 and is currently located in Cambridge, Massachusetts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless the context otherwise requires, references in these notes to “Gemini”, “the Company”, “we”, “us” and “our” and any related terms are intended to mean Gemini Therapeutics, Inc. and its consolidated subsidiary following the Business Combination (as defined below).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its inception, the Company has devoted substantially all its efforts and financial resources to organizing and staffing the Company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for our product candidates. The Company’s lead product candidate, GEM103, is currently in Phase 2a clinical development and its other product candidate, GEM307, is in the preclinical stage of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 5, 2021 (the “Closing Date”), FS Development Corporation, a Delaware corporation (“FSDC”), consummated the previously announced business combination (the “Business Combination”) pursuant to the terms of the Agreement and Plan of Merger, dated as of October 15, 2020 (as amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among Gemini Therapeutics, Inc., a Delaware corporation (“Old Gemini”), Shareholder Representative Services LLC, a Colorado limited liability company solely in its capacity as the representative, agent and attorney-in-fact of the Company Securityholders (the “Stockholders’ Representative”), FSDC and FSG Merger Sub Inc., a Delaware corporation (“Merger Sub”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FSDC was incorporated in Delaware on June 25, 2020 and was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On the day prior to the Closing Date, Old Gemini changed its name to “Gemini Therapeutics Sub, Inc.” Pursuant to the Merger Agreement, on the Closing Date, (i) FSDC changed its name to “Gemini Therapeutics, Inc.” and (ii) Old Gemini merged with and into Merger Sub (the “Merger”), with Old Gemini as the surviving company in the Merger and, after giving effect to such Merger, Old Gemini becoming a wholly-owned subsidiary of Gemini. Upon the closing of the Business Combination, and pursuant to the terms of the Merger Agreement, the existing shareholders of Old Gemini exchanged their interests for shares of common stock of Gemini.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Business Combination, certain investors purchased an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company’s Common Stock in a private placement of public equity (the “PIPE Financing”). Together with FSDC’s cash resources and funding of the PIPE Financing, the Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">195.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional information on the Business Combination, please refer to Note 3, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business Combination</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, to these condensed consolidated financial statements.</span></p>
CY2021Q3 us-gaap Cash Available For Distributions
CashAvailableForDistributions
150100000
CY2021Q1 gmtx Net Proceeds From Business Combination
NetProceedsFromBusinessCombination
195900000
CY2021Q3 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
21000000.0
gmtx Equity Issuance Costs And Other Costs
EquityIssuanceCostsAndOtherCosts
20960000
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
195882000
CY2021Q1 gmtx Number Of Shares Issued Due To Business Combination And Private Investment In Public Equity
NumberOfSharesIssuedDueToBusinessCombinationAndPrivateInvestmentInPublicEquity
25041150
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42998664
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates contained within these financial statements include, but are not limited to, the accruals of research and development expenses, share-based awards utilized for stock-based compensation purposes and, prior to the Business Combination, the estimated fair value of the Company’s common stock and warrant liability. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions.</span></p>
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
300000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
300000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150069000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4503000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
323000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
323000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150392000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4826000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of credit risk and of significant suppliers</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in accredited financial institutions in amounts that could exceed federally insured limits. Cash equivalents are invested in money market funds. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p>
us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Shorter of the useful life of the assetor the life of the lease
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
15257
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
15257
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.46
CY2019Q1 gmtx Contractual Term Of Issuance
ContractualTermOfIssuance
P10Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
15257
CY2020Q4 gmtx Warrant Liability
WarrantLiability
76000
gmtx Exercise Of Warrants
ExerciseOfWarrants
76000
CY2021Q3 gmtx Warrant Liability
WarrantLiability
0
CY2021Q3 gmtx Accrued Payroll And Benefits
AccruedPayrollAndBenefits
1832000
CY2020Q4 gmtx Accrued Payroll And Benefits
AccruedPayrollAndBenefits
1500000
CY2021Q3 gmtx Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
4482000
CY2020Q4 gmtx Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
3136000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
371000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
691000
CY2021Q3 gmtx Accrued Interest
AccruedInterest
21000
CY2020Q4 gmtx Accrued Interest
AccruedInterest
437000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46000
CY2021Q3 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6722000
CY2020Q4 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5810000
CY2020Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14000000.0
CY2020Q3 gmtx Accrued Simple Interest
AccruedSimpleInterest
0.08
CY2021Q3 us-gaap Other Expenses
OtherExpenses
0
us-gaap Other Expenses
OtherExpenses
700000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
14000000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2311000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11689000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11689000
CY2021Q3 us-gaap Interest Expense Customer Deposits
InterestExpenseCustomerDeposits
0
CY2020Q3 us-gaap Interest Expense Customer Deposits
InterestExpenseCustomerDeposits
1900000
us-gaap Interest Expense Customer Deposits
InterestExpenseCustomerDeposits
1700000
us-gaap Interest Expense Customer Deposits
InterestExpenseCustomerDeposits
1900000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10003000
us-gaap Net Income Loss
NetIncomeLoss
-54046000
us-gaap Net Income Loss
NetIncomeLoss
-26522000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43091822
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15282987
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39427476
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15016038
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 gmtx Preferred Stock Shares Outstanding1
PreferredStockSharesOutstanding1
0
CY2021Q3 gmtx Preferred Stock Shares Issued1
PreferredStockSharesIssued1
0
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1659000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
161000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6114000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
393000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18551000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.77
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4988293
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1985547
CY2021Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
100000
CY2021Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
11

Files In Submission

Name View Source Status
0000950170-21-004464-index-headers.html Edgar Link pending
0000950170-21-004464-index.html Edgar Link pending
0000950170-21-004464.txt Edgar Link pending
0000950170-21-004464-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmtx-20210930.htm Edgar Link pending
gmtx-20210930.xsd Edgar Link pending
gmtx-20210930_cal.xml Edgar Link unprocessable
gmtx-20210930_def.xml Edgar Link unprocessable
gmtx-20210930_htm.xml Edgar Link completed
gmtx-20210930_lab.xml Edgar Link unprocessable
gmtx-20210930_pre.xml Edgar Link unprocessable
gmtx-ex10_1.htm Edgar Link pending
gmtx-ex10_2.htm Edgar Link pending
gmtx-ex31_1.htm Edgar Link pending
gmtx-ex31_2.htm Edgar Link pending
gmtx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending